0KHE.LSE Revvity
- Market cap
- -
- P/E
- 23.3x
- P/B
- -
- ROE
- 2.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0KHE.LSE undervalued?
Graham numberThe Graham number of Revvity cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Revvity fundamental analysis
No fundamental analysis for Revvity yet.
Revvity stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Revvity
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for …
Full company profileRevvity financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Revvity annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.12B | 2.26B | 2.78B | 2.88B | 2.66B | 3.83B | 3.31B | 2.75B | 2.76B | 2.86B | 2.88B |
| Gross Profit | 1.01B | 1.07B | 1.34B | 1.40B | 2.11B | 2.47B | 1.99B | 1.54B | 1.54B | 1.23B | 1.34B |
| Operating Income | 283M | 305M | 324M | 362M | 867M | 1.26B | 743M | 301M | 347M | 357M | 404M |
| EBITDA | 406M | 425M | 519M | 610M | 1.20B | 1.62B | 1.30B | 714M | 840M | 766M | 842M |
| Net Income | 234M | 157M | 238M | 228M | 728M | 943M | 569M | 693M | 270M | 242M | 185M |
| EPS | 2.12 | 1.42 | 2.13 | 2.04 | 6.49 | 8.08 | 4.50 | 5.55 | 2.20 | 2.08 | 1.66 |
| Balance Sheet | |||||||||||
| Total Assets | 4.28B | 6.09B | 5.98B | 6.54B | 8.01B | 15.0B | 14.1B | 13.6B | 12.4B | 12.2B | 12.0B |
| Total Liabilities | 2.12B | 3.59B | 3.39B | 3.73B | 4.27B | 7.89B | 6.73B | 5.69B | 4.73B | 4.92B | 4.82B |
| Shareholders' Equity | 2.15B | 2.50B | 2.58B | 2.81B | 3.74B | 7.13B | 7.39B | 7.87B | 7.67B | 7.25B | 7.23B |
| Cash & Short-term Investments | 359M | 202M | 163M | 192M | 402M | 603M | 454M | 1.60B | 1.16B | 920M | 1.02B |
| Total Debt | 1.05B | 2.01B | 1.89B | 2.26B | 2.22B | 5.17B | 4.60B | 4.07B | 3.33B | 3.52B | 3.34B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 351M | 288M | 311M | 363M | 892M | 1.41B | 680M | 91.3M | 628M | 582M | 614M |
| Capital Expenditure | 31.7M | 39.1M | 93.3M | 81.3M | 77.5M | 99.9M | 85.6M | 81.4M | 86.6M | 73.5M | 61.7M |
| Free Cash Flow | 319M | 249M | 218M | 282M | 815M | 1.31B | 594M | 9.90M | 542M | 508M | 552M |
| Ratios | |||||||||||
| ROE | 10.9% | 6.3% | 9.2% | 8.1% | 19.5% | 13.2% | 7.7% | 8.8% | 3.5% | 3.3% | 2.6% |
| ROA | 5.5% | 2.6% | 4.0% | 3.5% | 9.1% | 6.3% | 4.0% | 5.1% | 2.2% | 2.0% | 1.5% |
| Net Profit Margin | 11.1% | 7.0% | 8.6% | 7.9% | 27.3% | 24.6% | 17.2% | 25.2% | 9.8% | 8.5% | 6.4% |
| Debt to Equity | 0.49x | 0.80x | 0.73x | 0.80x | 0.59x | 0.72x | 0.62x | 0.52x | 0.43x | 0.48x | 0.46x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Revvity dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 13.6%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 32.8M | 0.28 | 13.6% |
| 2024 | USD 34.5M | 0.28 | 12.7% |
| 2023 | USD 35.0M | 0.28 | 5.0% |
| 2022 | USD 35.3M | 0.28 | 6.2% |
| 2021 | USD 32.4M | 0.28 | 3.4% |
| 2020 | USD 31.2M | 0.28 | 4.3% |
| 2019 | 31.1M | 0.28 | 13.6% |
| 2018 | 31.0M | 0.28 | 13.0% |
| 2017 | USD 30.8M | 0.28 | 19.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Revvity
- Insiders 0.26%
- Institutions 99.74%
- Public & others 0.00%
- Free float 102M
Revvity company profile
- Company name
- Revvity
- Ticker
- 0KHE.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 11,000
- Fiscal year end
- January
- Address
- 77 4th Avenue, Waltham, MA, United States, 02451
- Phone
- 781 663 6900
- Website
- revvity.com
About Revvity
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Revvity management
10- Dr. Prahlad R. Singh Ph.D.CEO, President & Director · born 1965
- Mr. Maxwell KrakowiakSenior VP & CFO · born 1990
- Mr. Tajinder S. VohraSenior Vice President of Global Operations · born 1966
- Mr. Joel S. GoldbergSenior VP of Administration, General Counsel & Secretary · born 1969
- Ms. Miriame VictorSenior Vice President & Chief Business Officer · born 1981
- Ms. Anita GonzalesChief Accounting Officer, VP & Controller · born 1976
- Mr. Bryan A. KippSenior VP of Technology & Licensing
- Dr. Madhuri Hegde FACMG, Ph.D.Senior VP & Chief Scientific Officer
- Mr. Stephen Barr WilloughbySenior VP of Investor Relations & Head of ESG
- Ms. Magali FourSenior VP and Chief People & Culture Officer